Literature DB >> 6420931

Application of sepharose-linked monoclonal antibodies for the immunoradiometric measurement of factor VIII-procoagulant antigen.

E C Veerman, H V Stel, J G Huisman, J A van Mourik.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420931     DOI: 10.1016/0049-3848(84)90157-9

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  5 in total

1.  Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry.

Authors:  J Spaargaren; P L Giesen; M P Janssen; J Voorberg; G M Willems; J A van Mourik
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

2.  Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene.

Authors:  C L Verweij; C J de Vries; B Distel; A J van Zonneveld; A G van Kessel; J A van Mourik; H Pannekoek
Journal:  Nucleic Acids Res       Date:  1985-07-11       Impact factor: 16.971

3.  The interaction between human blood-coagulation factor VIII and von Willebrand factor. Characterization of a high-affinity binding site on factor VIII.

Authors:  A Leyte; M P Verbeet; T Brodniewicz-Proba; J A Van Mourik; K Mertens
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

4.  Human factor VIII procoagulant protein. Monoclonal antibodies define precursor-product relationships and functional epitopes.

Authors:  C A Fulcher; J R Roberts; L Z Holland; T S Zimmerman
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

5.  Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.

Authors:  A Leyte; K Mertens; B Distel; R F Evers; M J De Keyzer-Nellen; M M Groenen-Van Dooren; J De Bruin; H Pannekoek; J A Van Mourik; M P Verbeet
Journal:  Biochem J       Date:  1989-10-01       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.